About: Mevidalen

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Mevidalen (developmental code name LY-3154207) is a dopaminergic drug which is under development for the treatment of Lewy body disease, including those with Parkinson's disease. It acts as a selective positive allosteric modulator (PAM) of the dopamine D1 receptor. The drug is orally active and crosses the blood–brain barrier. It is a tetrahydroisoquinoline and is a close analogue of DETQ, another D1 receptor PAM. Mevidalen has been found to have wakefulness-promoting effects in sleep-deprived humans. Side effects of mevidalen have been reported to include increased heart rate and blood pressure, insomnia, dizziness, nausea, vomiting, anxiety, nervousness, fatigue, headaches, palpitations, and contact dermatitis, as well as falls in those with dementia. As of March 2022, mevidalen is in p

Property	Value
dbo:abstract	Mevidalen (developmental code name LY-3154207) is a dopaminergic drug which is under development for the treatment of Lewy body disease, including those with Parkinson's disease. It acts as a selective positive allosteric modulator (PAM) of the dopamine D1 receptor. The drug is orally active and crosses the blood–brain barrier. It is a tetrahydroisoquinoline and is a close analogue of DETQ, another D1 receptor PAM. Mevidalen has been found to have wakefulness-promoting effects in sleep-deprived humans. Side effects of mevidalen have been reported to include increased heart rate and blood pressure, insomnia, dizziness, nausea, vomiting, anxiety, nervousness, fatigue, headaches, palpitations, and contact dermatitis, as well as falls in those with dementia. As of March 2022, mevidalen is in phase 2 clinical trials for the treatment of Lewy body disease. Besides for movement disorders and dementia, D1 receptor PAMs like mevidalen might have value in the treatment of certain neuropsychiatric disorders, such as depression, excessive somnolence, and attention deficit hyperactivity disorder. (en)
dbo:casNumber	1638667-79-4
dbo:chEMBL	3421729
dbo:fdaUniiCode	4A3702A96F
dbo:kegg	D11826
dbo:pubchem	86290953
dbo:thumbnail	wiki-commons:Special:FilePath/Mevidalen.svg?width=300
dbo:wikiPageExternalLink	https://adisinsight.springer.com/drugs/800042093
dbo:wikiPageID	70823831 (xsd:integer)
dbo:wikiPageLength	7260 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1089938215 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Blood_pressure dbr:Dementia dbr:Depression_(mood) dbr:Dopaminergic dbr:Structural_analog dbr:Wakefulness-promoting_agent dbc:Alcohols dbc:Chloroarenes dbc:Experimental_drugs dbc:Ketones dbc:Tertiary_alcohols dbr:Contact_dermatitis dbr:Nausea dbr:Oral_administration dbr:Anxiety dbr:Lewy_body_disease dbr:Clinical_trial dbr:Positive_allosteric_modulator dbc:D1-receptor_agonists dbr:Heart_rate dbr:Fatigue_(medical) dbr:Sleep_deprivation dbr:Palpitation dbr:Parkinson's_disease dbr:Falling_(accident) dbr:Vomiting dbr:Headache dbr:Tetrahydroisoquinoline dbr:Attention_deficit_hyperactivity_disorder dbc:Amides dbc:Tetrahydroisoquinolines dbr:Binding_selectivity dbr:Blood–brain_barrier dbr:Dizziness dbr:Dopamine dbr:D1_receptor dbr:Insomnia dbr:Side_effect dbr:Phases_of_clinical_research dbr:Movement_disorder dbr:Neuropsychiatric_disorder dbr:Excessive_somnolence
dbp:c	24 (xsd:integer)
dbp:casNumber	1638667 (xsd:integer)
dbp:chembl	3421729 (xsd:integer)
dbp:chemspiderid	58985571 (xsd:integer)
dbp:cl	2 (xsd:integer)
dbp:h	29 (xsd:integer)
dbp:iupacName	2 (xsd:integer)
dbp:iupharLigand	10506 (xsd:integer)
dbp:kegg	D11826 (en)
dbp:n	1 (xsd:integer)
dbp:o	3 (xsd:integer)
dbp:pubchem	86290953 (xsd:integer)
dbp:smiles	C[C@H]1C2=CC=CCCCCO (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	XHCSBQBBGNQINS-DOTOQJQBSA-N (en)
dbp:synonyms	LY-3154207; LY3154207 (en)
dbp:unii	4 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Infobox_drug dbt:Nervous-system-drug-stub dbt:Reflist dbt:Dopamine_receptor_modulators
dct:subject	dbc:Alcohols dbc:Chloroarenes dbc:Experimental_drugs dbc:Ketones dbc:Tertiary_alcohols dbc:D1-receptor_agonists dbc:Amides dbc:Tetrahydroisoquinolines
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug
rdfs:comment	Mevidalen (developmental code name LY-3154207) is a dopaminergic drug which is under development for the treatment of Lewy body disease, including those with Parkinson's disease. It acts as a selective positive allosteric modulator (PAM) of the dopamine D1 receptor. The drug is orally active and crosses the blood–brain barrier. It is a tetrahydroisoquinoline and is a close analogue of DETQ, another D1 receptor PAM. Mevidalen has been found to have wakefulness-promoting effects in sleep-deprived humans. Side effects of mevidalen have been reported to include increased heart rate and blood pressure, insomnia, dizziness, nausea, vomiting, anxiety, nervousness, fatigue, headaches, palpitations, and contact dermatitis, as well as falls in those with dementia. As of March 2022, mevidalen is in p (en)
rdfs:label	Mevidalen (en)
owl:sameAs	wikidata:Mevidalen https://global.dbpedia.org/id/GPWhr
prov:wasDerivedFrom	wikipedia-en:Mevidalen?oldid=1089938215&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Mevidalen.svg
foaf:isPrimaryTopicOf	wikipedia-en:Mevidalen
is dbo:wikiPageRedirects of	dbr:LY-3154207 dbr:LY3154207 dbr:LY_3154207
is dbo:wikiPageWikiLink of	dbr:LY-3154207 dbr:LY3154207 dbr:LY_3154207
is foaf:primaryTopic of	wikipedia-en:Mevidalen